<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551159</url>
  </required_header>
  <id_info>
    <org_study_id>D419LC00001</org_study_id>
    <nct_id>NCT02551159</nct_id>
  </id_info>
  <brief_title>Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer</brief_title>
  <acronym>KESTREL</acronym>
  <official_title>A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine&#xD;
      the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus&#xD;
      SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior&#xD;
      systemic chemotherapy for recurrent or metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in a 2:1:1 ratio to MEDI4736 + tremelimumab combination therapy,&#xD;
      MEDI4736 monotherapy, or SoC. Patients in all arms will continue therapy until progression.&#xD;
      Tumor assessments will be performed on computed tomography scans or magnetic resonance&#xD;
      imaging scans, preferably with intravenous (IV) contrast. Efficacy for all patients will be&#xD;
      assessed by objective tumor assessments every 6 weeks for the first 24 weeks, then every 8&#xD;
      weeks thereafter until treatment discontinuation due to progression or toxicity. All patients&#xD;
      will be followed every 3 months for survival after progression is confirmed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2015</start_date>
  <completion_date type="Actual">May 21, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)</measure>
    <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
    <description>Number of participants with Overall Survival (OS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup</measure>
    <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
    <description>Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)</measure>
    <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
    <description>Number of participants with Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup</measure>
    <time_frame>12, 18 and 24 months after randomization</time_frame>
    <description>Percentage of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup</measure>
    <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
    <description>Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup</measure>
    <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
    <description>Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: &gt;= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup</measure>
    <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
    <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Status in the All-comers (Full Analysis Set)</measure>
    <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
    <description>Number of participants with Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)</measure>
    <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
    <description>Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)</measure>
    <time_frame>12, 18 and 24 months after randomization</time_frame>
    <description>Percentage of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in the All-comers (Full Analysis Set)</measure>
    <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
    <description>Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression).&#xD;
Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in the All-comers (Full Analysis Set)</measure>
    <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
    <description>Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: &gt;= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) in the All-comers (Full Analysis Set)</measure>
    <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
    <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">823</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736+Tremelimumab combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>Anti-PD-L1 antibody</description>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Anti-CTLA-4 Antibody</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736+Tremelimumab</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Monoclonal Antibody</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil (5FU)</intervention_name>
    <description>Chemotherapy Agent</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Chemotherapy agent</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Chemotherapy Agent</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years at the time of screening&#xD;
&#xD;
          2. Documented evidence of recurrent or metastatic SCCHN (oral cavity, oropharynx,&#xD;
             hypopharynx, or larynx).&#xD;
&#xD;
          3. A fresh tumor biopsy for the purpose of screening or an available archival tumor&#xD;
             sample. Tumor lesions used for fresh biopsies should not be the same lesions used as&#xD;
             RECIST target lesions, unless there are no other lesions suitable for biopsy.&#xD;
&#xD;
          4. No prior systemic chemotherapy for recurrent or metastatic disease&#xD;
&#xD;
          5. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             status of 0 or 1 at enrollment&#xD;
&#xD;
          6. No prior exposure to immune-mediated therapy,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed head and neck cancer of any other primary&#xD;
             anatomic location in the head and neck not specified in the inclusion criteria&#xD;
             including patients with SCCHN of unknown primary or non-squamous histologies (eg,&#xD;
             nasopharynx or salivary gland)&#xD;
&#xD;
          2. Tumor progression or recurrence within 6 months of last dose of platinum therapy in&#xD;
             the primary treatment setting&#xD;
&#xD;
          3. Receipt of any radiotherapy or hormonal therapy for cancer treatment within 30 days&#xD;
             prior to first dose of study treatment&#xD;
&#xD;
          4. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Olsson</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_official>
    <last_name>Tanguy Seiwert</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florianópolis</city>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ijui</city>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90619-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <zip>50040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <zip>09080-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo André</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>124 61</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <zip>711 11</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bengaluru</city>
        <zip>560076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karamsad</city>
        <zip>388325</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madurai</city>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cona</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akashi-shi</city>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>811-1347</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirakata-shi</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isehara-shi</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Natori-shi</city>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama-shi</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyoake-shi</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hwasun-gun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seo-Gu</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Pinas</city>
        <zip>1740</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1112</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bielsko-Biała</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-780</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suceava</city>
        <zip>720237</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620905</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 91</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badajoz</city>
        <zip>06008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marbella</city>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kapitanivka Village</city>
        <zip>08111</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv Region</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirovohrad</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ha Noi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh city</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419LC00001&amp;amp;attachmentIdentifier=b4025180-dfd4-4783-a723-cba099a5d9fb&amp;amp;fileName=D419LC00001_-_Protocol_v12__-redact.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419LC00001&amp;amp;attachmentIdentifier=0a933c97-43c4-4fdc-8e9f-af78f3808b67&amp;amp;fileName=D419LC00001_-_SAP_v7,0_-_redact.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419LC00001&amp;amp;attachmentIdentifier=da78c143-9577-4556-a890-e24f765e4d5f&amp;amp;fileName=D419LC00001_-_CSR_Synposis_-_28Apr2021-redact.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <results_first_submitted>July 5, 2021</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2021</results_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen 4 {CTLA-4}, PFS, SCCHN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02551159/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02551159/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients meeting all the eligibility criteria were randomized 2:1:1 to durvalumab plus tremelimumab combination therapy, durvalumab monotherapy or standard of care.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Durvalumab + Tremelimumab</title>
          <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
        </group>
        <group group_id="P2">
          <title>Durvalumab</title>
          <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
        </group>
        <group group_id="P3">
          <title>Standard of Care (SOC)</title>
          <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="204"/>
                <participants group_id="P3" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="204"/>
                <participants group_id="P3" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PD-L1 TC/IC High Subgroup Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="204"/>
                <participants group_id="P3" count="206"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="161"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patients alive or lost to follow-up at DCO</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Durvalumab + Tremelimumab</title>
          <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
        </group>
        <group group_id="B2">
          <title>Durvalumab</title>
          <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
        </group>
        <group group_id="B3">
          <title>Standard of Care (SOC)</title>
          <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="413"/>
            <count group_id="B2" value="204"/>
            <count group_id="B3" value="206"/>
            <count group_id="B4" value="823"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="9.56"/>
                    <measurement group_id="B2" value="60.2" spread="10.41"/>
                    <measurement group_id="B3" value="60.9" spread="9.45"/>
                    <measurement group_id="B4" value="60.5" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)</title>
        <description>Number of participants with Overall Survival (OS)</description>
        <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)</title>
          <description>Number of participants with Overall Survival (OS)</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Voluntary Discontinuation by subject</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive or lost to follow up</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of number of deaths</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.787</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup</title>
        <description>Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)</description>
        <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup</title>
          <description>Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="9.5" upper_limit="13.9"/>
                    <measurement group_id="O2" value="10.9" lower_limit="9.0" upper_limit="14.3"/>
                    <measurement group_id="O3" value="10.9" lower_limit="8.3" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)</title>
        <description>Number of participants with Overall Survival (OS)</description>
        <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)</title>
          <description>Number of participants with Overall Survival (OS)</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.634</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup</title>
        <description>Percentage of patients alive</description>
        <time_frame>12, 18 and 24 months after randomization</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup</title>
          <description>Percentage of patients alive</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="42.0" upper_limit="56.2"/>
                    <measurement group_id="O2" value="48.0" lower_limit="37.8" upper_limit="57.4"/>
                    <measurement group_id="O3" value="44.0" lower_limit="33.6" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="25.3" upper_limit="38.5"/>
                    <measurement group_id="O2" value="34.7" lower_limit="25.5" upper_limit="44.1"/>
                    <measurement group_id="O3" value="30.8" lower_limit="21.6" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="18.0" upper_limit="30.1"/>
                    <measurement group_id="O2" value="27.6" lower_limit="19.2" upper_limit="36.6"/>
                    <measurement group_id="O3" value="26.4" lower_limit="17.8" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup</title>
        <description>Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup</title>
          <description>Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.6" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.7" upper_limit="4.2"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.3" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.287</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup</title>
        <description>Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: &gt;= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)</description>
        <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup</title>
          <description>Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: &gt;= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of number with a response</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of number with a response</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup</title>
        <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression</description>
        <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
        <population>PD-L1 TC/IC subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup</title>
          <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression</description>
          <population>PD-L1 TC/IC subgroup</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.5" upper_limit="16.1"/>
                    <measurement group_id="O2" value="12.3" lower_limit="5.6" upper_limit="NA">The upper confidence limit was not calculable because of an insufficient number of participants with events.</measurement>
                    <measurement group_id="O3" value="4.2" lower_limit="3.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Status in the All-comers (Full Analysis Set)</title>
        <description>Number of participants with Overall Survival (OS)</description>
        <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
        <population>All-comers (Full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Status in the All-comers (Full Analysis Set)</title>
          <description>Number of participants with Overall Survival (OS)</description>
          <population>All-comers (Full analysis set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Voluntary Discontinuation by subject</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive or lost to follow up</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of number of deaths</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.811</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of number of deaths</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.624</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)</title>
        <description>Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)</description>
        <time_frame>From date of randomization until time of final analysis, an average of approximately 4 years</time_frame>
        <population>All-comers (Full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)</title>
          <description>Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)</description>
          <population>All-comers (Full analysis set)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="9.6" upper_limit="12.2"/>
                    <measurement group_id="O2" value="9.9" lower_limit="8.9" upper_limit="11.9"/>
                    <measurement group_id="O3" value="10.3" lower_limit="9.0" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)</title>
        <description>Percentage of patients alive</description>
        <time_frame>12, 18 and 24 months after randomization</time_frame>
        <population>All-comers (Full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)</title>
          <description>Percentage of patients alive</description>
          <population>All-comers (Full analysis set)</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="41.6" upper_limit="51.2"/>
                    <measurement group_id="O2" value="42.8" lower_limit="35.9" upper_limit="49.5"/>
                    <measurement group_id="O3" value="43.8" lower_limit="36.8" upper_limit="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="26.3" upper_limit="35.2"/>
                    <measurement group_id="O2" value="31.2" lower_limit="24.9" upper_limit="37.7"/>
                    <measurement group_id="O3" value="29.7" lower_limit="23.5" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="18.9" upper_limit="27.0"/>
                    <measurement group_id="O2" value="24.7" lower_limit="18.9" upper_limit="30.8"/>
                    <measurement group_id="O3" value="23.2" lower_limit="17.6" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) in the All-comers (Full Analysis Set)</title>
        <description>Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression).&#xD;
Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
        <population>All-comers (Full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) in the All-comers (Full Analysis Set)</title>
          <description>Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression).&#xD;
Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>All-comers (Full analysis set)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.0" upper_limit="2.8"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.4" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) in the All-comers (Full Analysis Set)</title>
        <description>Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: &gt;= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)</description>
        <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
        <population>All-comers (Full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) in the All-comers (Full Analysis Set)</title>
          <description>Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: &gt;= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)</description>
          <population>All-comers (Full analysis set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>2 sided</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR) in the All-comers (Full Analysis Set)</title>
        <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression</description>
        <time_frame>Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years</time_frame>
        <population>All-comers (Full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab</title>
            <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care (SOC)</title>
            <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR) in the All-comers (Full Analysis Set)</title>
          <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression</description>
          <population>All-comers (Full analysis set)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="6.0" upper_limit="19.6"/>
                    <measurement group_id="O2" value="11.9" lower_limit="4.6" upper_limit="17.8"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.7" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events will be collected from the time of signature of informed consent throughout the treatment period and including the follow-up period (up to 90 days after the last dose of investigational product or until initiation of another therapy) for an average of approximately 4 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Durvalumab + Tremelimumab</title>
          <description>tremelimumab (75 mg) via IV infusion every 4 weeks for a maximum of 4 doses, and durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
        </group>
        <group group_id="E2">
          <title>Durvalumab</title>
          <description>durvalumab (1500 mg) via IV infusion every 4 weeks until disease progression</description>
        </group>
        <group group_id="E3">
          <title>Standard of Care (SOC)</title>
          <description>either cisplatin (at a dose of 100 mg/m2 of body surface area as an IV infusion) or carboplatin (at an area under the concentration curve of 5 mg/mL/min as an IV infusion) on Day 1 of up to six 3-week cycles, and an infusion of 5-fluorouracil (5FU) (at a dose of 1000 mg/m2/day on Days 1 through 4) every 3 weeks, along with 400 mg/m2 of cetuximab on Cycle 1 Day 1 and 250 mg/m2 weekly for up to 6 cycles and maintenance cetuximab at 250 mg/m2 administered via IV infusion weekly thereafter in patients who achieved stable disease (SD) or better upon completion of chemotherapy until disease progression, toxicity, or withdrawal of consent</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="356" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lymph node haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="408"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Gastrostomy failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Troponin t increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="182" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="68" subjects_affected="61" subjects_at_risk="408"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="202"/>
                <counts group_id="E3" events="97" subjects_affected="65" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="48" subjects_affected="26" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="103" subjects_affected="63" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="76" subjects_affected="39" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="79" subjects_affected="68" subjects_at_risk="408"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="72" subjects_affected="59" subjects_at_risk="408"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="202"/>
                <counts group_id="E3" events="68" subjects_affected="54" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="113" subjects_affected="70" subjects_at_risk="408"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" events="96" subjects_affected="60" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="408"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="52" subjects_at_risk="408"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" events="120" subjects_affected="74" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="408"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" events="54" subjects_affected="40" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="52" subjects_affected="34" subjects_at_risk="408"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" events="66" subjects_affected="39" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="52" subjects_at_risk="408"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" events="61" subjects_affected="38" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="74" subjects_affected="66" subjects_at_risk="408"/>
                <counts group_id="E2" events="41" subjects_affected="35" subjects_at_risk="202"/>
                <counts group_id="E3" events="68" subjects_affected="56" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" events="58" subjects_affected="43" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="54" subjects_affected="48" subjects_at_risk="408"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" events="33" subjects_affected="21" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="24" subjects_affected="21" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="27" subjects_at_risk="408"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="36" subjects_affected="24" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" events="47" subjects_affected="22" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="408"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="57" subjects_affected="52" subjects_at_risk="408"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E3" events="59" subjects_affected="46" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="27" subjects_affected="16" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" events="77" subjects_affected="45" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="408"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" events="42" subjects_affected="22" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="408"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="408"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="408"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="408"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" events="50" subjects_affected="36" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" events="34" subjects_affected="26" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="61" subjects_affected="45" subjects_at_risk="408"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="62" subjects_affected="50" subjects_at_risk="408"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E3" events="114" subjects_affected="81" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="23" subjects_affected="18" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="408"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" events="19" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca Clinical Study Information Center</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

